Benzinga · Mar 6, 2026
Citigroup Maintains Neutral on Sight Sciences, Lowers Price Target to $6.5
Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and lowers the price target from $9.1 to $6.5.
SG
NASDAQ · SGHT
Sight Sciences, Inc.
Healthcare · Medical - Devices
$8.41
Up+$0.02 (+0.24%)
Updated Aug 28, 2026, 4:16 PM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 437.78M
- P/E ratio
- -9.41
- Dividend yield
- 0.00%
- 52-week range
- $3.19 – $9.24
- Volume
- 165.31K
- Avg. volume
- 190.46K
Price performance
SGHT price history
1M range · 21 trading sessions · Daily adjusted prices
SGHT closed at $8.41 after 21 trading sessions, up 59.89% for the selected period.
- Last close
- $8.41
- Period change
- +59.89%
- Period low
- $5.26
- Period high
- $8.47
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $8.30 | $8.548 | $8.25 | $8.41 | 165.31K |
| Aug 26, 2026 | $8.30 | $8.435 | $8.18 | $8.37 | 117.67K |
| Aug 25, 2026 | $8.37 | $8.42 | $8.205 | $8.32 | 125.84K |
| Aug 24, 2026 | $8.23 | $8.50 | $8.20 | $8.38 | 169.68K |
| Aug 21, 2026 | $8.25 | $8.35 | $8.05 | $8.26 | 180.59K |
| Aug 20, 2026 | $8.36 | $8.448 | $8.13 | $8.15 | 162.76K |
| Aug 19, 2026 | $8.44 | $8.85 | $8.3349 | $8.47 | 465.13K |
| Aug 18, 2026 | $8.23 | $8.45 | $8.00 | $8.22 | 300.45K |
| Aug 17, 2026 | $8.10 | $8.40 | $7.89 | $8.24 | 471.75K |
| Aug 14, 2026 | $8.34 | $8.47 | $8.0901 | $8.14 | 332.03K |
| Aug 13, 2026 | $8.40 | $8.60 | $8.2343 | $8.32 | 306.75K |
| Aug 12, 2026 | $7.76 | $8.41 | $7.6051 | $8.28 | 487.94K |
| Aug 11, 2026 | $7.76 | $8.11 | $7.65 | $7.75 | 321.46K |
| Aug 10, 2026 | $7.47 | $7.93 | $7.47 | $7.70 | 297.64K |
| Aug 7, 2026 | $7.24 | $7.60 | $7.03 | $7.47 | 374.79K |
| Aug 6, 2026 | $5.79 | $7.17 | $5.695 | $7.09 | 778.38K |
| Aug 5, 2026 | $5.77 | $5.77 | $5.25 | $5.55 | 460.87K |
| Aug 4, 2026 | $5.53 | $5.839 | $5.515 | $5.64 | 644.22K |
| Aug 3, 2026 | $5.35 | $5.65 | $5.05 | $5.53 | 178.03K |
| Jul 31, 2026 | $5.26 | $5.31 | $5.10 | $5.26 | 95.84K |
| Jul 30, 2026 | $5.33 | $5.46 | $5.24 | $5.26 | 82.97K |
Latest SGHT news
The latest Smart Investors Daily articles mentioning SGHT.
Stock researchCompany · Overview
SGHT research
Overview
Company profile and research snapshot.
Company profile
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $8.00
- Implied upside
- —
- Analysts
- 13
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | UBS | Buy | — |
| Jul 8, 2026 | Citigroup | Neutral | — |
| May 28, 2026 | Citigroup | Neutral | — |
| Mar 6, 2026 | Citigroup | Neutral | — |
| Mar 6, 2026 | UBS | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 5, 2026
Sight Sciences shares are trading lower after the company reported worse-than-expected Q4 sales results.
ChartMill · Mar 4, 2026
Sight Sciences Inc (NASDAQ:SGHT) Reports Mixed Q4 2025 Results, Beats on EPS but Misses Revenue
Sight Sciences reports mixed Q4 2025 results, beating EPS estimates but slightly missing revenue forecasts. The company also issued its 2026 financial guidance.
SeekingAlpha · Mar 4, 2026
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
